Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02939495
Other study ID # NEU-16.12
Secondary ID 16-NEU-1
Status Completed
Phase Phase 4
First received
Last updated
Start date October 2016
Est. completion date August 2017

Study information

Verified date May 2019
Source Neutec Ar-Ge San ve Tic A.S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Dapoxetine/Sildenafil 30/50 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.


Description:

During 4-weeks treatment period, patients will take one Dapoxetine/Sildenafil 30/50 mg film coated tablet 1-3 hours before sexual intercourse.

Study drug should not be used more than 1 tablet every 24 hours during the treatment.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date August 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- 18-64 years old men,

- Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,

- Clinical diagnosis of erectile dysfunction, IIEF score =21,

- Premature Ejaculation Diagnostic Tool (PEDT) score must be =11

- Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,

- The patient and his partner must have sexual intercourse twice a week for the duration of the study,

- Commitment to comply with the study protocol,

- Patients who sign informed consent form (ICF).

Exclusion Criteria:

- History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,

- Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,

- Developed ED or PE due to drug use or quit taking drugs,

- Any conditions that prevent sexual intercourse with partners

- History of epilepsy,

- Severe renal insufficiency,

- Liver disease,

- History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), AV block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension,

- Non-Arteritic Anterior ischemic optic neuropathy,

- Patients who are not eligible to have sexual intercourse due to existing health problems,

- Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,

- Systolic/Diastolic blood pressure at rest <90/50mmHg and 170/100mmHg<

- History of allergy to Selective Serotonine Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,

- Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonine Reuptake Inhibitor (SSRI), Selective-Norepinephrin Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,

- Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erithromicin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, PDE5 inhibitor, alcohol and stimulant drug,

- Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment

- During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties

- Patients who are defining symptoms of prostatitis clinically

- Thyroid hormone disorders

Study Design


Intervention

Drug:
Dapoxetine/Sildenafil 30/50 mg film coated tablet
1 tablet before sexual intercourse

Locations

Country Name City State
Turkey Bagcilar Research and Training Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Tuken M, Culha MG, Serefoglu EC. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study. Int J Impot Res. 2019 Mar;31(2):92-96. doi: 10.1038/ — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline. 4-weeks
Primary The evaluation of IIEF-15 (International Index of Erectile Function Questionnaire) score compared to baseline. 4-weeks
Primary The evaluation of premature ejaculation symptom scores compared to baseline. 4-weeks
Secondary The evaluation of Premature Ejaculation response measured by Premature Ejaculation Profile (PEP) 4-weeks
Secondary The Rate of Premature Ejaculation Profile (PEP) response 4-weeks
Secondary The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment) 4-weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05366504 - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment Phase 2/Phase 3
Recruiting NCT02573805 - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02225548 - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Phase 4
Completed NCT02587988 - Trial to Evaluate the Efficacy and Safety of HCP1302 Phase 3
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT02945462 - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED) Phase 1
Completed NCT01698684 - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Phase 4
Not yet recruiting NCT01321489 - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies Phase 3
Terminated NCT01262833 - Pudendal Assessment in Erectile Dysfunction N/A
Completed NCT01230541 - Effect of Udenafil on Spermatogenesis Phase 1
Completed NCT02226237 - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy N/A
Completed NCT01037244 - Treatment of Erectile Dysfunction I Phase 3
Completed NCT01037218 - Treatment of Erectile Dysfunction II Phase 3
Recruiting NCT00313898 - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Phase 4
Completed NCT00421083 - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Phase 3
Completed NCT00667979 - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Phase 4
Completed NCT00663728 - Assessment of Duration of Erection With Vardenafil 10 mg Phase 4